IGFBP7 and neoplasm: Targeting the CD93-IGFBP7 axis, using monoclonal antibodies reverses the properties associated with the abnormal tumor vasculature structure, including hypoxia, vessel leakage, and immunosuppression, leading to an improved ICB response [104].